Successful clinical trials have shown industry stakeholders the value cell and gene therapy (CGT) offers patients now and as the path of future medicine.
Despite the clinical benefits, CGT has not yet achieved significant market penetration. In addition to struggling with production roadblocks, companies also face pricing issues and a global healthcare system unprepared for CGT roll out.
This roundtable will identify successful strategies that underpin currently-marketed therapies and examine how establishing a framework early in development helps keep long-term production and commercialisation goals on track.
On-Demand Webinar Archive
To access the archived recording of this webinar, visit our webinar channel and complete a one time only form. This will give you access to our entire library of archived webinars.
Access Webinar ArchiveICON presenter
Tamie Joeckel
Cell and Gene Therapy Global Business Lead, ICON
Tamie Joeckel has over 20 years of experience in both commercialization services and clinical operations for specialty biologics – with the last 6 years focused on cell and gene therapies. Prior to that, she was certified in production and inventory management (CPIM) working as an ERP systems consultant for process manufacturing systems and ISO certification. In commercial distribution, Tamie led teams that designed and implemented commercialization strategies and patient hub services solutions for specialty biologics requiring REMS programs and patient registries for oncology and rare disease therapies. For the last 6 years, Tamie has worked as an operations and logistics orchestration expert for cell and gene therapy programs, designing global depot and distribution strategies for these highly sensitive “living therapies”. Tamie is based in Houston, Texas and is an active member of both the Alliance for Regenerative Medicine and NORD.